Olema Stock Up 242%, but Does a $122 Million Position Suggest More Upside Potential? | The Motley Fool
Olema Pharmaceuticals develops targeted therapies for women's cancers, with a lead program advancing in clinical trials for breast cancer.

Source: The Motley Fool
Olema Pharmaceuticals develops targeted therapies for women's cancers, with a lead program advancing in clinical trials for breast cancer.